Shenzhen MagicRNA Biotechnology Co., Ltd. (hereinafter referred to as MagicRNA) was one of the seventh batch of innovative enterprises selected by Shenzhen Industrial Innovation Center for Engineering Biology. On January 20, 2022, MagicRNA Biology was established in December 2021 and officially settled in the Innovation Center on January 20, 2022, which is an enterprise engaged in research and development of RNA innovative drugs.
In the Chinese name of the company, “hong” implies “a rainbow shining on mountains and rivers”; “xin” implies “integrity, the foundation of business development”. MagicRNA embraces the ideal of “creating a healthy future”, taking innovation, integrity, responsibility and openness as the cornerstone, to work hard on nucleic acid delivery, and benefit patients with RNA therapy.
The company officially graduated from the Innovation Center on October 25, 2022. Before leaving, its team said, “Since settling in the Innovation Center, the project has been advanced rapidly thanks to the excellent innovation and entrepreneurship environment and complete infrastructure and shared high-end laboratory equipment. During this period when we embarked on the right track, we were most deeply impressed by the professionalism of the Innovation Center. We are sincerely grateful to all the professionals of the Innovation Center for the rapid development of the start-up MagicRNA.”
The company is now located in the Smart Park of Investment Promotion Bureau of Guangming District, Shenzhen, with a total area of 2,700 square meters. The R & D center and GMP pilot base have been partially put into operation. At present, the innovative drug research and development team of MagicRNA has gathered top talents in the industry, over 80% of whom have an academic degree of master and above. It has established three core technology platforms for mRNA sequence design, mRNA efficient synthesis and LNP efficient delivery, so as to realize the rapid development and industrialization of RNA drugs, especially mRNA drugs. So far, several mRNA drugs of the company are under the stage of pre-clinical research.
In the field of lipid nanoparticles (LNP) delivery, the company has applied for a number of invention patents, two of which have been authorized. Now, it has the largest ionized amino lipid bank with fully independent intellectual property rights in China. Based on the ionized amino lipids with independent intellectual property rights, the delivery system developed by the company has taken the lead in China in terms of in vivo activity and magnification. At present, the company has received investment of the seed round (with a fund of millions of yuan) and the angel round (with a fund of tens of millions of yuan).
In the future, the company will work hard on nucleic acid delivery oriented around clinical demands, benefit patients with RNA therapy, continue to conquer clinically incurable diseases with RNA technology, and build an excellent pharmaceutical enterprise with innovative research and development and industrial transformation as its dual cores.